![Evgeny Zaytsev](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Evgeny Zaytsev
Founder at Bering Capital LLC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
George Lasezkay | M | 72 | 7 years | |
Tuomas R. Holmberg | M | - |
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 19 years |
Wendy Siu | F | - |
Asset Management Co.
![]() Asset Management Co. Investment ManagersFinance Asset Management Co. is a venture capital firm. The company was founded in 1965 and is headquartered in East Palo Alto, CA. | 17 years |
Philip Sawyer | M | 59 |
Bering Capital LLC
![]() Bering Capital LLC Investment ManagersFinance Bering Capital LLC (Bering Capital) is a venture capital firm founded in 2020 by Evgeny Zaytsev. The firm is headquartered in San Francisco, California. | 4 years |
Richard Croarkin | M | 69 | 8 years | |
Jeffrey Edwards | M | 63 | 6 years | |
Michael Timothy Cooke | M | 65 |
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 15 years |
Barbara H. Bauschka | F | - | 8 years | |
Sergey Beloborodov | M | - |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Vladimir Avetissian | M | - |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Emil Gafarov | M | - |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | 11 years |
Rick McElheny | M | - | 8 years | |
Vladimir Oskarovich Gurdus | M | 59 |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | 12 years |
Nikolay Batulin | M | - |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Yurij Udaltsov | M | - |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Jennifer Aaker | M | 57 |
Stanford Graduate School of Business
| 23 years |
Inna Martin Eitan | F | - |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Pavel Rodyukov | M | - |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Maxim Gorbachev | M | 48 |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
John P. Hennessey | M | - |
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 15 years |
Allison Hulme | M | 61 |
InteKrin Therapeutics, Inc.
![]() InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | 11 years |
Leonid Melamed | M | 63 |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Olga Yuryevna Shpichko | M | 49 |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | - |
Andrey Borisovich Malyshev | M | 64 |
RMI Partners OOO
![]() RMI Partners OOO Investment ManagersFinance RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. | 12 years |
John E. Edwards | M | - |
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 19 years |
Mike Knych | M | - |
Asset Management Co.
![]() Asset Management Co. Investment ManagersFinance Asset Management Co. is a venture capital firm. The company was founded in 1965 and is headquartered in East Palo Alto, CA. | 18 years |
Wendye Robbins | M | 63 |
Stanford University
| 20 years |
Bill McDonough | M | - |
Stanford University
| 20 years |
Martha Morrell | M | 66 |
Stanford University
| 20 years |
Rich Simoni | M | - |
Asset Management Co.
![]() Asset Management Co. Investment ManagersFinance Asset Management Co. is a venture capital firm. The company was founded in 1965 and is headquartered in East Palo Alto, CA. | 22 years |
Skip Fleshman | M | - |
Asset Management Co.
![]() Asset Management Co. Investment ManagersFinance Asset Management Co. is a venture capital firm. The company was founded in 1965 and is headquartered in East Palo Alto, CA. | 22 years |
Todd Brady | M | 52 |
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 17 years |
R. Gordon Douglas | M | 89 |
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | - |
Viral Kansara | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Kryzwicki | M | - |
Stanford University
| 7 years |
Leslie B. Zacks | M | 55 | 4 years | |
Sam L. Shrank | M | - |
Stanford University
| 5 years |
Mike Jackson | M | - |
Stanford University
| 5 years |
Nathan Evans | M | - |
Stanford University
| 6 years |
Ben S. Abadi | M | - |
Stanford University
| 4 years |
Nafis Jamal | M | - |
Stanford University
| 4 years |
Alex W. Bergman | M | - |
Stanford University
| 2 years |
Amit Garg | M | - |
Stanford University
| 5 years |
Sampath Jinadasa | M | - |
Stanford University
| 5 years |
Enrique Allen | M | - |
Stanford University
| 6 years |
Jennifer T. Forster | F | - |
Stanford Graduate School of Business
Stanford University
| 2 years |
Eric Kroll | M | - |
Stanford University
| 2 years |
Renata Streit Quintini | F | - |
Stanford University
| 4 years |
Derek Yoon | M | 49 | 2 years | |
Ian Wong | M | 38 |
Stanford University
| 5 years |
Seth Silverman | M | - |
Stanford University
| 5 years |
Whitney Gaynor | F | - |
Stanford University
| 6 years |
Magdalena Jonikas | F | - |
Stanford University
| 5 years |
Dustin Espersen | M | - |
Stanford University
| 5 years |
Todd Jackson | M | - |
Stanford University
| 4 years |
William Chan | M | - |
Stanford University
| 3 years |
Ibrahim Almojel | M | - |
Stanford University
| 6 years |
Argyrios Zymnis | M | - |
Stanford University
| 5 years |
David Topham | M | - |
Stanford University
| 4 years |
Christina Cacioppo | F | - |
Stanford University
| 5 years |
Jenny P. Chen | F | - |
Stanford University
| 3 years |
Gerald D. Cagle | M | 79 | 5 years | |
Thomas Joseph Berrings | M | - |
Stanford University
| 4 years |
George Oji | M | - |
Stanford University
| 4 years |
Megan V. Hansen | F | - |
Stanford University
| 4 years |
McClure Kelly | M | - |
Stanford University
| 2 years |
Joseph Mayer | M | - |
Stanford University
| 4 years |
Jennifer Carolan | F | - |
Stanford University
| 2 years |
Adrian Li | M | - |
Stanford University
| 2 years |
Donald F. Cass | M | 57 |
Stanford University
| 4 years |
Ian Carmichael | M | - |
Stanford University
| 4 years |
Andy L. Evans | M | 62 |
Stanford University
| 2 years |
Michael Donner | M | - |
Stanford University
| 2 years |
Nick Weiksner | M | - |
Stanford University
| 4 years |
Olga Borisovna Grigoryeva | F | 57 |
Altai State University
| 4 years |
Rafal Styczen | M | 53 |
Stanford University
| 1 years |
Zhenan Bao | M | - |
Stanford University
| - |
Raphael Lucien de Balmann | M | - |
Stanford University
| 3 years |
Paul D. Greene | M | 46 |
Stanford University
| 2 years |
Ee-Ping Ong | M | - |
Stanford University
| 2 years |
Krishna Gorti | M | - |
Stanford University
| 2 years |
Aviva Aminova | M | - |
Stanford University
| 4 years |
Susan Docherty | F | 61 |
Stanford University
| 1 years |
Tom Montgomery | M | 38 |
Stanford University
| 4 years |
Martin Casado | M | - |
Stanford University
| 1 years |
Saloni Multani | F | 45 |
Stanford University
| 2 years |
Meera Venu | F | - |
Stanford University
| 4 years |
Martin Sumner | M | 50 |
Stanford University
| 2 years |
Kirthiga Reddy | F | 52 |
Stanford University
| 2 years |
Na Xin Yao | M | 54 |
Stanford University
| 2 years |
Lesley A. Bunim | F | - |
Stanford University
| 2 years |
Brad Pereira | M | - |
Stanford University
| 4 years |
Anthony J. Limberis | M | - |
Stanford University
| 2 years |
Paul M. Tiger | M | - |
Stanford University
| 3 years |
Christof Wittig | M | - |
Stanford University
| 1 years |
Edward S. Chung | M | - |
Stanford University
| 2 years |
Rick Wedell | M | - |
Stanford University
| 2 years |
Daniel J. Estes | M | 43 |
Stanford University
| 1 years |
Ulf Waschbusch | M | - |
Stanford University
| 2 years |
Minal Mehta | F | - |
Stanford University
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 87 | 87.00% |
Russia | 12 | 12.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Evgeny Zaytsev
- Personal Network